WHAT IS CLAIMED IS:

1. A method of preventing or treating neoplasia disorders and neoplasia disorder-related complications in a subject that is in need of such prevention or treatment comprising administering to the subject a Cox-2 inhibitor in combination with an EGF receptor antagonist.

2. The method according to claim 1, wherein the Cox-2 inhibitor and EGF receptor antagonist is administered to the subject in combination with one or more antineoplastic agents.

3. The method according to claim 1, wherein the Cox-2 inhibitor comprises a non-steroidal anti-inflammatory drug.

4. The method according to claim 1, wherein the Cox-2 inhibitor is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, diclofenac, fenclofenec, alclofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin, acetyl salicylic acid, indometacin, piroxicam, tenoxicam, nabumetone, ketorolac, azapropazone, mefenamic acid, tolfenamic acid, diflunisal, podophyllotoxin derivatives, acemetacin, droxicam, floctafenine, oxyphenbutazone, phenylbutazone, proglumetacin, acemetacin, fentiazac, clidanac, oxipinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flufenisal, sudoxicam, etodolac, piprofen, salicylic acid, choline magnesium trisalicylate, salicylate, benorylate, fentiazac, clopinac, feprazone, isoxicam and 2-fluoro-a-methyl[1,1'-biphenyl]-4-acetic acid, 4-(nitrooxy)butyl ester.

5. The method according to claim 1, wherein the Cox-2 inhibitor comprises a Cox-2 selective inhibitor.

6. The method according to claim 5, wherein the Cox-2 selective inhibitor is selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, etoricoxib, meloxicam, rofecoxib, lumiracoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, darbufelone, CS-502, LAS-34475, LAS-34555, S-33516, SD-8381, prodrugs of any of them, and mixtures thereof.

7. The method according to claim 5, wherein the Cox-2 selective inhibitor is selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, etoricoxib, meloxicam, rofecoxib, lumiracoxib, prodrugs of any of them, and mixtures thereof.

8. The method according to claim 5, wherein the Cox-2 selective inhibitor comprises celecoxib.

9. The method according to claim 2, wherein the antineoplastic agent is selected from the group consisting of antimetabolite agents, alkylating agents, antibiotic-type agents, hormonal anticancer agents, immunological agents, interferon-type agents, prodrugs of any of them, and mixtures thereof.

10. The method according to claim 2, wherein the antineoplastic agent is a taxane derivative.

11. The method according to claim 10, wherein the taxane derivative is paclitaxel.

12. The method according to claim 1, wherein the EGF receptor antagonist is selected from the group consisting of 4-aminoquinazolines, potato carboxypeptidase inhibitor, tyrosine kinase inhibitor, bombesin antagonist RC-3095, quinazolines, pyridopyrimidines, pyrimidopyrimidines, pyrrolopyrimidines, pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d] pyrimidines, curcumin, 4,5-bis (4-fluoroanilino)phthalimide, tyrphostins containing nitrothiophene moieties, benzothiazoles, paeciloquinones, cinnoline derivatives, EGF receptor antisense molecules, substituted styrenes, anti-EGF receptor antibodies and dianilinopthalimides, prodrugs of any of them, and mixtures thereof.

13. The method according to claim 1, wherein the EGF receptor antagonist is selected from the group consisting of AGM-1470, reveromycin A, TNP-470, PD-171026, PD-089828, PD-090560, ZM-254530, ZM-105180, EGF-genistein, wayne anti-EGFR Mabs, anti-VEGF monoclonal, Genen EMD-72000, anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ABX-EGF, anti-EGFr MAb, anti-EGFR-DM1 Ab, anti-EGFR conjugate, anti-flk-1 MAb DC-101, bromelain molecules, CCX, CCZ, tecogalan sodium, platelet factor 4, Inhibitors of vascular endothelial growth factor antagonist (VEGF) and its receptor flk-1, 4-(3-Ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline hydrochloride, ZD-1838, ZD-1839, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamin o]phenyl]benzamide, CGP-59326, CGP-79787 CGP-59326B, CGP-62706, CGP-74321, CGP-75166, CGP-76627, DWP-408, muellerian-inhibiting hormone, 4-(m-chloro)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine, 5-[3-[3-methoxy-4-[2-[(E)-2-phenylethenyl]-4-oxazolylmethoxy]phenyl]propyl]-3-[2-[(E)-2-phenylethenyl]-4-oxazolylmethyl]-2,4-oxazolidinedione, N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine, PI-88, PJ3505, S-96-8045, 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)cinnoline, N-[4-[(3-chloro-4-fluorophenyl) amino]-7-[3-(4-morpholinyl) propoxy]-6-quinazolinyl]-2-propenamide, EKB-569,

PTK787, HER-2/neu protein antibody, EGF receptor antibody, trastuzumab, GEM-220 AR-639, MDX-447, MDX-260, DAB-720, HER-2 antagonist, VRCTC-310, MR1scFvPE38KDEL, EMD-55900, EGF fusion toxin, OLX-103, Selex, CGP-62706, SU-5271, NX-278-L, metalloprotease inhibitor, EGF fusion protein, Amphiregulin, CGP-52411, AG-1478, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, QX-101, SU-5271, flavopiridol, SU-101, celastrol, CGP-52411, anti-flk-1, CEP-2563, HER-2 antagonist, NSC-675967, SU-5416, FCE-26806, DAB-720, CEP-751, ZD-1838, CGP-60261, EGF-RTK antagonist, ALL-TK antagonists, GRB2 antagonists, CGP-57148, ZD-1839, erbB-2 receptor inhibitors, PD-158780, benzothiazoles, PD-171026, BE-23372M derivatives, Met TK antagonist, PD-159973, GW-282974, CP-292597, ZM-105180, GW-7072X, Lck tyrosine kinase inhibitors, PD-168393, PD-173956, RG-14620, CGP-59326, genistein, FCE-27119, RG-13022, RG-50864, PD-154233, TT-232, AG-514, AG-568, PD-151514, BE-23372M, KW-6151, paeciloquinones, PDGFrTK inhibitors, SDZ-LAP-977, CGP-53716, CGP-79787, B43-genistein, CGP-62706, AG-957, erlotinib, iressa, cetuximab, trastuzumab-DM1, mono[3-butyl-8-(9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8- nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7- dioxaspiro[5.5]undec-3-yl] ester, Imatinib mesylate, trastuzumab, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline, [(dimethylamino)methyl]acrylo-para-[(hydroxy-benzoylsulfonyl)-oxy]phenone, cetuximab, theraCIM h-R3, erlotinib in combination with taxotere, C1033, EKB-569, ior-egf/r3, EGF-genistein, anti-EGFr MAb, anti-EGFR-DM1 Ab, anti-EGFR conjugate, EGFR conjugate, CI-1033, GW-211, PKI-166, STI571, BIBX1522, 4-(phenylamino)quinazolines, EGF receptor antisense oligonucleotide, amphiregulin, EGF fusion protein, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline analogues, 4-[ar(alk)ylamino]pyridopyrimidines, GW2974, GW9263, GW4263, GW0277, GW5289, GW5949, GW9525, GW572016, PD13530, CGP5211, CGP53353, CGP 75166/PKI166, BIBX 1382, EKB-569, CI-

1033, GW-2016, EMD- 72000, MDX-210, 2C4, TgDCC-E1A, prodrugs of any of them, and mixtures thereof.

14. The method according to claim 1, wherein the EGF receptor antagonist is selected from the group consisting of AGM-1470, reveromycin A, TNP-470, PD-171026, PD-089828, PD-090560, ZM-254530, ZM-105180, EGF-genistein, wayne anti-EGFR Mabs, anti-VEGF monoclonal, Genen EMD-72000, anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ABX-EGF, anti-EGFr MAb, anti-EGFr Mab, anti-EGFR-DM1 Ab, anti-EGFR conjugate, anti-flk-1 MAb DC-101, bromelain molecules, CCX, CCZ, tecogalan sodium, platelet factor 4, Inhibitors of vascular endothelial growth factor antagonist (VEGF) and its receptor flk-1, 4-(3-Ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline hydrochloride, ZD-1838, ZD-1839, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamin o]phenyl]benzamide, CGP-59326, CGP-79787 CGP-59326B, CGP-62706, CGP-74321, CGP-75166, CGP-76627, DWP-408, EGF-genistein, muellerian-inhibiting hormone, 4-(m-chloro)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine, 5-[3-[3-methoxy-4-[2-[(E)-2-phenylethenyl]-4-oxazolylmethoxy]phenyl]propyl]-3-[2-[(E)-2-phenylethenyl]-4-oxazolylmethyl]-2,4-oxazolidinedione, N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine, PI-88, PJ3505, S-96-8045, 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)cinnoline, N-[4-[(3-chloro-4-fluorophenyl) amino]-7-[3-(4-morpholinyl) propoxy]-6-quinazolinyl]-2-propenamide, EKB-569, PTK787, HER-2/neu protein antibody, EGF receptor antibody, trastuzumab, GEM-220 AR-639, MDX-447, MDX-260, DAB-720, HER-2 antagonist, VRCTC-310, MR1scFvPE38KDEL, ABX-EGF, EMD-55900, EMD-72000, EGF fusion toxin, OLX-103, Selex, CGP-62706, SU-5271, NX-278-L, metalloprotease inhibitor, EGF fusion protein, Amphiregulin, SU-5271, CGP-52411, AG-1478, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, QX-101, SU-5271, flavopiridol, SU-101,

celastrol, CGP-52411, anti-flk-1, CEP-2563, HER-2 antagonist, NSC-675967, SU-5416, FCE-26806, DAB-720, CEP-751, ZD-1838, CGP-60261, EGF-RTK antagonist, ALL-TK antagonists, GRB2 antagonists, CGP-57148, ZD-1839, erbB-2 receptor inhibitors, PD-158780, benzothiazoles, PD-171026, BE-23372M derivatives, Met TK antagonist, PD-159973, GW-282974, CP-292597, ZM-105180, GW-7072X, Lck tyrosine kinase inhibitors, PD-168393, PD-173956, RG-14620, CGP-59326, genistein, FCE-27119, RG-13022, RG-50864, PD-154233, TT-232, AG-514, AG-568, PD-151514, BE-23372M, KW-6151, paeciloquinones, PDGFrTK inhibitors, SDZ-LAP-977, CGP-53716, CGP-79787, B43-genistein, CGP-62706, AG-957, *erlotinib*, *iressa*, *cetuximab*, trastuzumab-DM1, mono[3-butyl-8-(9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8- nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7-dioxaspiro[5.5]undec-3-yl] ester, Imatinib mesylate, trastuzumab, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline, [(dimethylamino)methyl]acrylo-para-[(hydroxy-benzoylsulfonyl)-oxy]phenone, *cetuximab*, theraCIM h-R3, erlotinib in combination with taxotere, C1033, ABX-EGF, EKB-569, anti-EGFR Mabs, EMD-72000; anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ior-egf/r3, EGF-genistein, ABX-EGF, anti-EGFr MAb, anti-EGFr MAb, anti-EGFR-DM1 Ab, anti-EGFR conjugate, EGFR conjugate, CI-1033, GW-211, PKI-166, STI571, BIBX1522, 4-(phenylamino)quinazolines, EGF receptor antisense oligonucleotide, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, CGP-52411, SU-5271, amphiregulin, EGF fusion protein, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline analogues, 4-[ar(alk)ylamino]pyridopyrimidines, (4-(phenylamino)quinazolines), GW2974, GW9263, GW4263, GW0277, GW5289, GW5949, GW9525, GW572016, PD13530, CGP5211, CGP53353, CGP 75166/PKI166, BIBX 1382, EKB-569, PKI-166, CI-1033, GW-2016, EMD- 72000, MDX-210, 2C4, TgDCC-E1A, prodrugs of any of them, and mixtures thereof.

15. The method according to claim 1, wherein the EGF receptor antagonist is selected from the group consisting of erlotinib, iressa, cetuximab, ABX-EGF, prodrugs of any of them, and mixtures thereof.

16. The method according to claim 1, wherein the EGF receptor antagonist is erlotinib.

17. The method according to claim 1, wherein the subject suffers from or is predisposed to one or more neoplasia disorders selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cycstic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, adrenocortical carcinoma, AIDS-related lymphoma, anal cancer, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bile duct cancer, bladder cancer, brain stem glioma, brain tumors, breast cancer, bronchial gland carcinomas, capillary carcinoma, carcinoids, carcinoma, carcinosarcoma, cavernous, central nervous system lymphoma, cerebral astrocytoma, cholangiocarcinoma, chondosarcoma, choriod plexus papilloma/carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, esophageal cancer, Ewing's sarcoma, extragonadal germ cell tumor, fibrolamellar, focal nodular hyperplasia, gallbladder cancer, gastrinoma, germ cell tumors, gestational trophoblastic tumor, glioblastoma, glioma, glucagonoma, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, Hodgkin's lymphoma, hypopharyngeal cancer, hypothalamic and visual pathway glioma, childhood, insulinoma, intaepithelial neoplasia, interepithelial squamous cell neoplasia, intraocular melanoma, invasive squamous cell carcinoma, large cell carcinoma, islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, lentigo maligna melanomas,

leukemia-related disorders, lip and oral cavity cancer, liver cancer, lung cancer, lymphoma, malignant mesothelial tumors, malignant thymoma, medulloblastoma, medulloepithelioma, melanoma, meningeal, merkel cell carcinoma, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, multiple myeloma/plasma cell neoplasm, mycosis fungoides, myelodysplastic syndrome, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, oat cell carcinoma, oligodendroglial, oral cancer, oropharyngeal cancer, osteosarcoma, pancreatic polypeptide, ovarian cancer, ovarian germ cell tumor, pancreatic cancer, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, parathyroid cancer, penile cancer, pheochromocytoma, pineal and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, small intestine cancer, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, supratentorial primitive neuroectodermal tumors, thyroid cancer, undifferentiatied carcinoma, urethral cancer, uterine sarcoma, uveal melanoma, verrucous carcinoma, vaginal cancer, vipoma, vulvar cancer, Waldenstrom's macroglobulinemia, well differentiated carcinoma, and Wilm's tumor.

18. The method according to claim 1, wherein the subject suffers from or is predisposed to colon cancer.

19. The method according to claim 1, further comprising administering an amount of a Cox-2 inhibitor and an amount of an EGF

receptor antagonist wherein the amount of the Cox-2 inhibitor and the amount of the EGF receptor antagonist together comprises a therapeutically effective amount.

20. The method according to claim 1, wherein the Cox-2 inhibitor and EGF receptor antagonist is administered to the subject in combination with one or more antineoplastic agents and the antineoplastic agent is other than a Cox-2 inhibitor and other than a EGF receptor antagonist.

21. A therapeutic composition comprising at least one Cox-2 inhibitor and one or more EGF receptor antagonists.

22. The therapeutic composition according to claim 21, wherein the Cox-2 inhibitor comprises a Cox-2 selective inhibitor.

23. The therapeutic composition according to claim 22, wherein the Cox-2 selective inhibitor is selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, etoricoxib, meloxicam, rofecoxib, lumiracoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, darbufelone, CS-502, LAS-34475, LAS-34555, S-33516, SD-8381, prodrugs of any of them, and mixtures thereof.

24. The therapeutic composition according to claim 21, further comprising one or more antineoplastic agents.

25. The therapeutic composition according to claim 21, wherein the EGF receptor antagonist is selected from the group consisting of AGM-1470, reveromycin A, TNP-470, PD-171026, PD-089828, PD-090560, ZM-254530, ZM-105180, EGF-genistein, wayne anti-EGFR Mabs, anti-VEGF monoclonal, Genen EMD-72000, anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ABX-EGF, anti-EGFr

MAb, anti-EGFr Mab, anti-EGFR-DM1 Ab, anti-EGFR conjugate, anti-flk-1 MAb DC-101, bromelain molecules, CCX, CCZ, tecogalan sodium, platelet factor 4, inhibitors of vascular endothelial growth factor antagonist (VEGF) and its receptor flk-1, 4-(3-Ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline hydrochloride, ZD-1838, ZD-1839, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamin o]phenyl]benzamide, CGP-59326, CGP-79787 CGP-59326B, CGP-62706, CGP-74321, CGP-75166, CGP-76627, DWP-408, EGF-genistein, muellerian-inhibiting hormone, 4-(m-chloro)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine, 5-[3-[3-methoxy-4-[2-[(E)-2-phenylethenyl]-4-oxazolylmethoxy]phenyl]propyl]-3-[2-[(E)-2-phenylethenyl]-4-oxazolylmethyl]-2,4-oxazolidinedione, N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine, PI-88, PJ3505, S-96-8045, 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)cinnoline, N-[4-[(3-chloro-4-fluorophenyl) amino]-7-[3-(4-morpholinyl) propoxy]-6-quinazolinyl]-2-propenamide, EKB-569, PTK787, HER-2/neu protein antibody, EGF receptor antibody, trastuzumab, GEM-220 AR-639, MDX-447, MDX-260, DAB-720, HER-2 antagonist, VRCTC-310, MR1scFvPE38KDEL, EMD-55900, EGF fusion toxin, OLX-103, Selex, CGP-62706, SU-5271, NX-278-L, metalloprotease inhibitor, EGF fusion protein, Amphiregulin, AG-1478, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, QX-101, SU-5271, flavopiridol, SU-101, celastrol, CGP-52411, anti-flk-1, CEP-2563, HER-2 antagonist, NSC-675967, SU-5416, FCE-26806, DAB-720, CEP-751, ZD-1838, CGP-60261, EGF-RTK antagonist, ALL-TK antagonists, GRB2 antagonists, CGP-57148, ZD-1839, erbB-2 receptor inhibitors, PD-158780, benzothiazoles, PD-171026, BE-23372M derivatives, Met TK antagonist, PD-159973, GW-282974, CP-292597, ZM-105180, GW-7072X, Lck tyrosine kinase inhibitors, PD-168393, PD-173956, RG-14620, CGP-59326, genistein, FCE-27119, RG-13022, RG-50864, PD-154233, TT-232, AG-514, AG-568, PD-151514, BE-23372M, KW-6151, paeciloquinones, PDGFrTK inhibitors, SDZ-LAP-977, CGP-53716, CGP-

79787, B43-genistein, CGP-62706, AG-957, erlotinib, iressa, cetuximab, trastuzumab-DM1, mono[3-butyl-8-(9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8- nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7-dioxaspiro[5.5]undec-3-yl] ester, imatinib mesylate, trastuzumab, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline, [(dimethylamino)methyl]acrylo-para-[(hydroxy-benzoylsulfonyl)-oxy]phenone, cetuximab, theraCIM h-R3, erlotinib in combination with taxotere, C1033, EKB-569, ior-egf/r3, CI-1033, GW-211, PKI-166, STI571, BIBX1522, 4-(phenylamino)quinazolines, EGF receptor antisense oligonucleotide, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline analogues, 4-[ar(alk)ylamino]pyridopyrimidines, GW2974, GW9263, GW4263, GW0277, GW5289, GW5949, GW9525, GW572016, PD13530, CGP5211, CGP53353, CGP 75166/PKI166, BIBX 1382, CI-1033, GW-2016, EMD- 72000, MDX-210, 2C4, TgDCC-E1A, prodrugs of any of them, and mixtures thereof.

26. The therapeutic composition according to claim 21, wherein the EGF receptor antagonist is selected from the group consisting of AGM-1470, reveromycin A, TNP-470, PD-171026, PD-089828, PD-090560, ZM-254530, ZM-105180, EGF-genistein, wayne anti-EGFR Mabs, anti-VEGF monoclonal, Genen EMD-72000, anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ABX-EGF, anti-EGFr MAb, anti-EGFr Mab, anti-EGFR-DM1 Ab, anti-EGFR conjugate, anti-flk-1 MAb DC-101, bromelain molecules, CCX, CCZ, tecogalan sodium, platelet factor 4, Inhibitors of vascular endothelial growth factor antagonist (VEGF) and its receptor flk-1, 4-(3-Ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline hydrochloride, ZD-1838, ZD-1839, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamin o]phenyl]benzamide, CGP-59326, CGP-79787 CGP-59326B, CGP-62706, CGP-74321, CGP-75166, CGP-76627, DWP-408, EGF-genistein, muellerian-inhibiting hormone, 4-(m-chloro)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine, 5-[3-[3-methoxy-4-[2-[(E)-2-phenylethenyl]-4-

oxazolylmethoxy]phenyl]propyl]-3-[2-[(E)-2-phenylethenyl]-4-oxazolylmethyl]-2,4-oxazolidinedione, N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine, PI-88, PJ3505, S-96-8045, 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)cinnoline, N-[4-[(3-chloro-4-fluorophenyl) amino]-7-[3-(4-morpholinyl) propoxy]-6-quinazolinyl]-2-propenamide, EKB-569, PTK787, HER-2/neu protein antibody, EGF receptor antibody, trastuzumab, GEM-220 AR-639, MDX-447, MDX-260, DAB-720, HER-2 antagonist, VRCTC-310, MR1scFvPE38KDEL, ABX-EGF, EMD-55900, EMD-72000, EGF fusion toxin, OLX-103, Selex, CGP-62706, SU-5271, NX-278-L, metalloprotease inhibitor, EGF fusion protein, Amphiregulin, SU-5271, CGP-52411, AG-1478, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, reveromycin-A, QX-101, SU-5271, flavopiridol, SU-101, celastrol, CGP-52411, anti-flk-1, CEP-2563, HER-2 antagonist, NSC-675967, SU-5416, FCE-26806, DAB-720, CEP-751, ZD-1838, CGP-60261, EGF-RTK antagonist, ALL-TK antagonists, GRB2 antagonists, CGP-57148, ZD-1839, erbB-2 receptor inhibitors, PD-158780, benzothiazoles, PD-171026, BE-23372M derivatives, Met TK antagonist, PD-159973, GW-282974, CP-292597, ZM-105180, GW-7072X, Lck tyrosine kinase inhibitors, PD-168393, PD-173956, RG-14620, CGP-59326, genistein, FCE-27119, RG-13022, RG-50864, PD-154233, TT-232, AG-514, AG-568, PD-151514, BE-23372M, KW-6151, paeciloquinones, PDGFrTK inhibitors, SDZ-LAP-977, CGP-53716, CGP-79787, B43-genistein, CGP-62706, AG-957, erlotinib, iressa, cetuximab, trastuzumab-DM1, mono[3-butyl-8-(9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8- nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7-dioxaspiro[5.5]undec-3-yl] ester, Imatinib mesylate, trastuzumab, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline, [(dimethylamino)methyl]acrylo-para-[(hydroxy-benzoylsulfonyl)-oxy]phenone, cetuximab, theraCIM h-R3, erlotinib in combination with taxotere, C1033, ABX-EGF, EKB-569, anti-EGFR Mabs, EMD-72000; anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ior-egf/r3, EGF-genistein, ABX-EGF, anti-EGFr

MAb, anti-EGFr MAb, anti-EGFR-DM1 Ab, anti-EGFR conjugate, EGFR conjugate, CI-1033, GW-211, PKI-166, STI571, BIBX1522, 4-(phenylamino)quinazolines, EGF receptor antisense oligonucleotide, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, CGP-52411, SU-5271, amphiregulin, EGF fusion protein, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline analogues, 4-[ar(alk)ylamino]pyridopyrimidines, (4-(phenylamino) quinazolines), GW2974, GW9263, GW4263, GW0277, GW5289, GW5949, GW9525, GW572016, PD13530, CGP5211, CGP53353, CGP 75166/PKI166, BIBX 1382, EKB-569, PKI-166, CI-1033, GW-2016, EMD- 72000, MDX-210, 2C4, TgDCC-E1A, prodrugs of any of them, and mixtures thereof.

27. The therapeutic composition according to claim 21, wherein the EGF receptor antagonist is erlotinib.

28. A pharmaceutical composition comprising at least one Cox-2 inhibitor, one or more EGF receptor antagonists, and a pharmaceutically acceptable carrier.

29. The pharmaceutical composition according to claim 28, further comprising one or more antineoplastic agents.

30. The pharmaceutical composition according to claim 28, wherein the Cox-2 inhibitor comprises a Cox-2 selective inhibitor.

31. The pharmaceutical composition according to claim 28, wherein the Cox-2 selective inhibitor is selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, etoricoxib, meloxicam, rofecoxib, lumiracoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, darbufelone, CS-502, LAS-34475, LAS-34555, S-33516, SD-8381, prodrugs of any of them, and mixtures thereof.

32. The pharmaceutical composition according to claim 28, wherein the EGF receptor antagonist is selected from the group consisting of AGM-1470, reveromycin A, TNP-470, PD-171026, PD-089828, PD-090560, ZM-254530, ZM-105180, EGF-genistein, wayne anti-EGFR Mabs, anti-VEGF monoclonal, Genen EMD-72000, anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ABX-EGF, anti-EGFr MAb, anti-EGFr Mab, anti-EGFR-DM1 Ab, anti-EGFR conjugate, anti-flk-1 MAb DC-101, bromelain molecules, CCX, CCZ, tecogalan sodium, platelet factor 4, Inhibitors of vascular endothelial growth factor antagonist (VEGF) and its receptor flk-1, 4-(3-Ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline hydrochloride, ZD-1838, ZD-1839, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamin o]phenyl]benzamide, CGP-59326, CGP-79787 CGP-59326B, CGP-62706, CGP-74321, CGP-75166, CGP-76627, DWP-408, EGF-genistein, muellerian-inhibiting hormone, 4-(m-chloro)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine, 5-[3-[3-methoxy-4-[2-[(E)-2-phenylethenyl]-4-oxazolylmethoxy]phenyl]propyl]-3-[2-[(E)-2-phenylethenyl]-4-oxazolylmethyl]-2,4-oxazolidinedione, N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine, PI-88, PJ3505, S-96-8045, 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)cinnoline, N-[4-[(3-chloro-4-fluorophenyl) amino]-7-[3-(4-morpholinyl) propoxy]-6-quinazolinyl]-2-propenamide, EKB-569, PTK787, HER-2/neu protein antibody, EGF receptor antibody, trastuzumab, GEM-220 AR-639, MDX-447, MDX-260, DAB-720, HER-2 antagonist, VRCTC-310, MR1scFvPE38KDEL, EMD-55900, EGF fusion toxin, OLX-103, SELEX, CGP-62706, SU-5271, NX-278-L, metalloprotease inhibitor, EGF fusion protein, Amphiregulin, SU-5271, CGP-52411, AG-1478, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, QX-101, SU-5271, flavopiridol, SU-101, celastrol, CGP-52411, anti-flk-1, CEP-2563, HER-2 antagonist, NSC-675967, SU-5416, FCE-26806, DAB-720, CEP-751, ZD-1838, CGP-60261, EGF-RTK antagonist, ALL-TK antagonists, GRB2 antagonists, CGP-57148, ZD-1839, erbB-2 receptor

inhibitors, PD-158780, benzothiazoles, PD-171026, BE-23372M derivatives, Met TK antagonist, PD-159973, GW-282974, CP-292597, ZM-105180, GW-7072X, Lck tyrosine kinase inhibitors, PD-168393, PD-173956, RG-14620, CGP-59326, genistein, FCE-27119, RG-13022, RG-50864, PD-154233, TT-232, AG-514, AG-568, PD-151514, BE-23372M, KW-6151, paeciloquinones, PDGFrTK inhibitors, SDZ-LAP-977, CGP-53716, CGP-79787, B43-genistein, CGP-62706, AG-957, erlotinib, iressa, cetuximab, trastuzumab-DM1, mono[3-butyl-8-(9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8- nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7- dioxaspiro[5.5]undec-3-yl] ester, Imatinib mesylate, trastuzumab, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline, [(dimethylamino)methyl]acrylo-para-[(hydroxy-benzoylsulfonyl)-oxy]phenone, cetuximab, theraCIM h-R3, erlotinib in combination with taxotere, C1033, EKB-569, ior-egf/r3, CI-1033, GW-211, PKI-166, STI571, BIBX1522, 4-(phenylamino)quinazolines, EGF receptor antisense oligonucleotide, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline analogues, 4-[ar(alk)ylamino]pyridopyrimidines, GW2974, GW9263, GW4263, GW0277, GW5289, GW5949, GW9525, GW572016, PD13530, CGP5211, CGP53353, CGP 75166/PKI166, BIBX 1382, CI-1033, GW-2016, EMD- 72000, MDX-210, 2C4, TgDCC-E1A, prodrugs of any of them, and mixtures thereof.

33. The pharmaceutical composition according to claim 28, wherein the EGF receptor antagonist is selected from the group consisting of AGM-1470, reveromycin A, TNP-470, PD-171026, PD-089828, PD-090560, ZM-254530, ZM-105180, EGF-genistein, wayne anti-EGFR Mabs, anti-VEGF monoclonal, Genen EMD-72000, anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ABX-EGF, anti-EGFr MAb, anti-EGFr Mab, anti-EGFR-DM1 Ab, anti-EGFR conjugate, anti-flk-1 MAb DC-101, bromelain molecules, CCX, CCZ, tecogalan sodium, platelet factor 4, Inhibitors of vascular endothelial growth factor antagonist (VEGF) and its receptor flk-1, 4-(3-Ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-

quinazoline hydrochloride, ZD-1838, ZD-1839, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl]benzamide, CGP-59326, CGP-79787 CGP-59326B, CGP-62706, CGP-74321, CGP-75166, CGP-76627, DWP-408, EGF-genistein, muellerian-inhibiting hormone, 4-(m-chloro)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine, 5-[3-[3-methoxy-4-[2-[(E)-2-phenylethenyl]-4-oxazolylmethoxy]phenyl]propyl]-3-[2-[(E)-2-phenylethenyl]-4-oxazolylmethyl]-2,4-oxazolidinedione, N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine, PI-88, PJ3505, S-96-8045, 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)cinnoline, N-[4-[(3-chloro-4-fluorophenyl) amino]-7-[3-(4-morpholinyl) propoxy]-6-quinazolinyl]-2-propenamide, EKB-569, PTK787, HER-2/neu protein antibody, EGF receptor antibody, trastuzumab, GEM-220 AR-639, MDX-447, MDX-260, DAB-720, HER-2 antagonist, VRCTC-310, MR1scFvPE38KDEL, ABX-EGF, EMD-55900, EMD-72000, EGF fusion toxin, OLX-103, Selex, CGP-62706, SU-5271, NX-278-L, metalloprotease inhibitor, EGF fusion protein, Amphiregulin, SU-5271, CGP-52411, AG-1478, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, QX-101, SU-5271, flavopiridol, SU-101, celastrol, CGP-52411, anti-flk-1, CEP-2563, HER-2 antagonist, NSC-675967, SU-5416, FCE-26806, DAB-720, CEP-751, ZD-1838, CGP-60261, EGF-RTK antagonist, ALL-TK antagonists, GRB2 antagonists, CGP-57148, ZD-1839, erbB-2 receptor inhibitors, PD-158780, benzothiazoles, PD-171026, BE-23372M derivatives, Met TK antagonist, PD-159973, GW-282974, CP-292597, ZM-105180, GW-7072X, Lck tyrosine kinase inhibitors, PD-168393, PD-173956, RG-14620, CGP-59326, genistein, FCE-27119, RG-13022, RG-50864, PD-154233, TT-232, AG-514, AG-568, PD-151514, BE-23372M, KW-6151, paeciloquinones, PDGFrTK inhibitors, SDZ-LAP-977, CGP-53716, CGP-79787, B43-genistein, CGP-62706, AG-957, erlotinib, iressa, cetuximab, trastuzumab-DM1, mono[3-butyl-8-(9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8- nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7-

dioxaspiro[5.5]undec-3-yl] ester, Imatinib mesylate, trastuzumab, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline, [(dimethylamino)methyl]acrylo-para-[(hydroxy-benzoylsulfonyl)-oxy]phenone, cetuximab, theraCIM h-R3, erlotinib in combination with taxotere, C1033, ABX-EGF, EKB-569, anti-EGFR Mabs, EMD-72000; anti-EGFR Mab, EMD-6200, MDX-447, BAB-447, EMD-82633, H-447, ior-egf/r3, EGF-genistein, ABX-EGF, anti-EGFr MAb, anti-EGFr MAb, anti-EGFR-DM1 Ab, anti-EGFR conjugate, EGFR conjugate, CI-1033, GW-211, PKI-166, STI571, BIBX1522, 4-(phenylamino)quinazolines, EGF receptor antisense oligonucleotide, RC-3940-II, CP-358774, C225, hbEGF-toxin, MAb 4D5, BBR-1611, PD-169450, CGP-52411, SU-5271, amphiregulin, EGF fusion protein, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline analogues, 4-[ar(alk)ylamino]pyridopyrimidines, (4-(phenylamino)quinazolines), GW2974, GW9263, GW4263, GW0277, GW5289, GW5949, GW9525, GW572016, PD13530, CGP5211, CGP53353, CGP 75166/PKI166, BIBX 1382, EKB-569, PKI-166, CI-1033, GW-2016, EMD- 72000, MDX-210, 2C4, TgDCC-E1A, prodrugs of any of them, and mixtures thereof.

34. A kit for preventing or treating neoplasia disorders and neoplasia disorder-related complications in a subject that is in need of such prevention or treatment, the kit comprising one dosage form comprising a Cox-2 inhibitor and a second dosage form comprising an EGF receptor antagonist.